Matt Hoffman

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Marwan Sabbagh, MD, FAAN. [LISTEN TIME: 21 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and related dementias.

As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased, and in recent years, GFAP has emerged as a valuable candidate to add to the existing panel.

The Elecsys pTau181 and Abeta42 cerebrospinal fluid assays achieved 90% concordance with amyloid PET scans, according to Roche’s announcement. The assays are approved for use with the cobas fully automated immunoassay analyzers.

Retrospective analysis of a group of individuals with stroke suggests that nonconvulsive acute symptomatic seizures are associated with long-term use of antiseizure medications, providing key data in guiding therapy use in this population.

Lucretia Long, APRN-CNP, an associate clinical professor of neurology at OSU Wexner Medical Center, offered her perspective on the benefits of having multiple specialists available to provide comprehensive care to patients.

Notably, though, cenobamate treatment was associated with weight reductions among patients who were categorized as overweight and obese, but not in those who were underweight or normal weight.

The investigational therapy from Xenon Pharmaceuticals showed marked reductions in monthly seizure frequency from months 14 to 20, with consistent safety and good retention rates.

A survey conducted in conjunction with the Dravet Syndrome Foundation suggests that many patients with DS do not undergo the transition of care from pediatric to adult neurology providers, with caregivers of those who did expressing some concerns about the process.

Data from the Pediatric Epilepsy Learning Healthcare System suggest that a variety of factors—including age, preference, insurance, and demographics—affect physician selection of antiseizure medications, with little standardization among this population.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Epilepsy Society.

Data from the BUTTERFLY study of 36 children with Dravet syndrome have provided 12-month measurements of neurodevelopment, clinical status, quality of life, and executive function. Investigators expressed that these data will help inform future trial outcome measures.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]

Experts in neurology discuss changes in cognitive health and the role that sphingosine-1-phospate receptor modulators and disease-modifying therapies play in MS management.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Bruce Cree, MD, PhD, MAS, FAAN, offered his perspective on data from the phase 2/3 N-MOmentum trial of the recently approved inebilizumab (Uplizna; Horizon Therapeutics) and why the therapy stands out from other NMOSD treatments.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with George Small, MD. [LISTEN TIME: 33 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

The Child Neurology Foundation is using community outreach and a new social services network to help children with neurological conditions feel included in contemporary society.

In addition to presenting data from the phase 3 KINECT-HD study of valbenazine in the treatment of chorea associated with Huntington disease, Neurocrine’s chief medical officer noted that the company recently submitted an sNDA to the FDA for the therapy.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

The brain monitoring platform can be used in a number of settings, including the ICU and doctor’s offices, to monitor and detect cognitive decline related to neurodegenerative disease, as well as screening in clinical trials.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Darin Okuda, MD; Federica Picariello, PhD; Brenda Banwell, MD; Riley Bove, MD; Tomas Kalincik, MD, PhD; and Marisa McGinley, DO. [LISTEN TIME: 34 minutes]

As patients with ALS may have altered taste perception and have expressed that bitterness is associated with AMX0035 (Relyvrio; Amylyx) administration, a number of coping strategies have suggested a workaround to ensure treatment adherence and effectiveness.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

AT-GAA, an Amicus Therapeutics treatment for late-onset Pompe disease consists of miglustat, an orally administered stabilizing agent, in combination with cipaglucosidase alfa, an infusion enzyme-replacing component.

In a late-breaking presentation in ECTRIMS, data from the MSBase international registry was suggestive of higher disability accumulation risk compared with those who did not experience relapse, in both treated and untreated patients with MS.